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population of patients with CHD. In addition, the intraop-
erative management strategies were not standardized. Fi-
nally, the predictive value of neurodevelopmental testing at
1 year is limited.20 The full extent of an early injury often is
not completely recognized until long after the event, when
complex cognitive and higher executive skills are required.
The larger APOE cohort is currently undergoing detailed
neurodevelopmental assessment at 4 years of age.
Conclusions
In this large, heterogeneous cohort of patients undergoing
repair of 2-ventricle CHD, patient-specific factors are im-
portant determinants of neurodevelopmental outcomes at 1
year of age and contribute more substantially to the risk of
adverse neurodevelopmental outcomes than do intraopera-
tive management strategies. Consistent with previous stud-
ies, intraoperative management strategies explain only a
small portion of the variability in outcomes. Previously
described risk factors (both patient-specific and intraopera-
tive variables) explain only part (30%) of the variability in
neurodevelopmental outcomes, suggesting that unrecognized
factors are important determinants of outcome. Genetic factors
are a major determinant of neurologic outcome in children with
CHD. Future studies of neurologic outcome and neuroprotec-
tive strategies must include risk-stratification for genetic and
other patient factors that may alter the risk of central nervous
system injury and adverse neurologic outcomes. These factors
may be more important determinants of outcome than are
intraoperative management strategies. To improve neurodevel-
opmental outcomes for children with CHD, we must identify
and understand the biologic pathways underlying interindi-
vidual variation in outcomes and develop individualized, tar-
geted therapeutic strategies.
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Discussion
Dr Richard A. Jonas (Washington, DC). I congratulate you and
your colleagues for providing some data that will help us to
unravel the specific impact of patient-related factors on neurode-
velopmental outcome before general cardiac surgery.
What you have done is to perform a meta-analysis of a pro-
spective but nonrandomized study of the impact of a specific
genotype on neurodevelopmental outcome. Not surprisingly, you
found that patient-specific factors were more important than intra-
operative manipulations such as the use of circulatory arrest,
hematocrit, or pH strategy.
I say “not surprisingly” because, as you yourself have pointed
out in the limitations of the study, this is a very heterogeneous
patient population. For example, unlike previous work in this area,
you included low birth weight patients and you included patients
with known genetic factors and confirmed what is widely known,
that both of these factors have an important impact on outcome.
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In addition, you made no attempt in your study to subject
patients to a uniform bypass strategy. The duration of cooling
before circulatory arrest in some patients was as short as 5 minutes,
and the lowest NP temperature recorded before circulatory arrest
was as high as 28°C.
I am concerned that the subliminal message that comes through
is that since patient-related factors are so important, we really do
not need to focus any attention on remediable intraoperative fac-
tors.
Surely you would agree that studies that have attempted to
enroll only a very homogeneous patient population and then have
subjected patients to a carefully controlled set of intraoperative
conditions with variation of only one factor, such as hematocrit or
pH, are far more likely to produce specific information regarding
the relative importance of intraoperative factors, and the conclu-
sions derived from such studies should be interpreted in that light.
My first question for you is to ask you, once again, why you
continue to use the alpha-stat strategy in patients in whom you are
considering using circulatory arrest despite the fact that a prospec-
tive, randomized trial of pH strategy documented a significantly
higher incidence of perioperative complications, including death to
a P value of .06, when the alpha-stat strategy was used.
I am also interested to know your current strategy regarding
hematocrit in patients in whom you intend to use DHCA. What do
you consider the current limits of a reasonable standard of care? As
we get asked regularly by the lawyers, what is a reasonable
standard of care currently for the application of DHCA in terms of
duration of cooling, minimum temperature for circulatory arrest,
and maximal duration?
Finally, I am interested to know what you believe the next step
will be, more specifically, in identifying and understanding the
biologic pathways that underlie individual variation in outcomes
and how you plan to move to developing individualized targeted
therapeutic strategies which, I agree, is certainly going to be a very
important development that is coming out of this important work
that you are doing.
I certainly do not want to downplay the importance of your
focus on patient-specific factors. These clearly are important fac-
tors, as we demonstrated in the circulatory arrest study. But I do
not think you should use the presence of important patient-specific
factors to downplay the fact that there may be differences in
outcome according to intraoperative strategies.
Dr Gaynor. First, I think it is important to recognize that even
though this is a prospective observational study in which manage-
ment strategies were not stratified, the findings are very consistent
with the other studies such as you mentioned, the hematocrit study,
the blood gas study, and the circulatory arrest study. The amount
of variability explained by DHCA is very consistent.
In your study of hematocrit, although hematocrit was the single
most important factor, you also found that birth weight (even
though you excluded low birth weight infants), preoperative intu-
bation, and other factors were significantly important determinants
of outcome.
In discussing the alpha-stat versus pH strategy, there were some
perioperative differences in outcome. However, as you acknowl-
edged, neither strategy was associated with improved or impaired
neurodevelopmental outcomes.
I pulled out the subgroup of patients who met the criteria for
entering the hematocrit study—no genetic syndromes, 2-ventricle
heart disease, birth weight greater than 2.3 kg—and looked at the
MDI and PDI for ours with an alpha-stat versus pH stat. The mean
PDI for your group was 85.6 and ours was 85.5 for similar patients.
The mean MDI for yours was, I think, 93-point something and ours
was 94. Thus I think the outcomes are very similar, even though
we used an alpha-stat and you used a pH-stat strategy, when the
patient populations are comparable.
In terms of the cooling for DHCA, there was one patient who
had a 1-minute period of circulatory arrest at 28°C. Everybody else
was cooled for at least 15 minutes, and I believe the median was
a little bit greater than that. That one patient is an outlier. We do,
indeed, cool at least 15 to 20 minutes before the use of circulatory
arrest. We have gone to a higher hematocrit on hemodilution. We
usually maintain a hematocrit level around 30% during hemodilu-
tion now when we are going to use DHCA.
I think the best data currently out there for duration are the
BCAS data, which suggest a safe duration somewhere, with the
strategies from the late 1980s, of around 40 minutes. I do not
propose that these data will tell us whether there is a safe duration
or not.
In the alpha-stat study and in the hematocrit study, approxi-
mately 40% of the patients had circulatory arrest. And circulatory
arrest was not a risk factor for outcome in either one of those
studies. So I wonder how much effect circulatory arrest has on
outcome.
What I think is important is that these studies have provided an
incredible amount of information, but I do not know how much
variability, how much more improvement in outcome, we are going
to get by changing the factors and applying them to the whole
population. I think there is good evidence that there are genetic
factors that affect the severity—the inflammatory response, coag-
ulation profiles, tolerance to ischemia—which vary significantly
across patient populations.
As we begin to understand, we may be able to identify high-risk
subgroups, for example, a child who is at a high risk for a
hyperinflammatory response or a child who is at risk for micro-
vascular coagulation. I do not know where the factors are going to
be. I think we are going to need a genetic association study in
much more detail than what I have done with one specific allele.
However, if we can identify genetic syndromes and biologic path-
ways that have relevance to the mechanism of injury, then perhaps
if a child produces a lot of tumor necrosis factor-, there may be
a monoclonal antibody against tumor necrosis factor- that will be
important for him. If the child is at risk for microvascular coagu-
lation, perhaps we need another type of anticoagulation. I do not
know, but I think that is the direction.
What I hope to do with this paper is to say that we need to focus
on some of these other factors because I think the amount we are
able to change the outcomes with our intraoperative strategies may
be limited. It is a testable hypothesis. We have to find out.
Dr Jonas. Regarding the specific changes that you might make,
depending on genetic subtype, patients at risk, what exactly would
be done?
Dr Gaynor. Well, I think you would have to define. There are
some studies in patients with sepsis. If you have identified that they
are at risk for a hyperinflammatory response, there are specific
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receptor blockers that can be used to treat them. If we can identify
these patients preoperatively, perhaps we should attempt to blunt
the inflammatory pathway in that subgroup of patients.
I do not have the specific treatment strategies yet, but I think
that is a focus that, as we go forward, we should begin to look at.
How are these patients different? One of the things that I found
striking in this was the tremendous variability in outcome in the
children who had continuous bypass. Even when we eliminated the
genetic syndrome patients, we still found the same patient factors
outweighed the variability of the operative factors.
Dr John E. Connolly (Irvine, Calif). I congratulate the authors
on their interesting findings as likely causes of poor neurodevel-
opment outcomes. I have several questions.
How did you monitor the infant’s temperature and how did you
decide how long to cool to obtain what you thought was a safe
degree of brain cooling? Did you use ice around the head of the
patient?
We have also been interested in the possible causes of supra-
tentorial damage from profound hypothermia and circulatory ar-
rest. To study that, we subjected 80 dogs of various ages to the
technique after our psychology department had conditioned them
to perform complicated tasks to be repeated after recovery from
the hypothermia and arrest. We used direct brain temperatures on
those dogs.
We first used deep hypothermia and arrest for open neurosur-
gical vascular procedures in which we could directly monitor the
brain with a thermistor probe in the cortex. We were very im-
pressed with the significant lag between the brain temperature and
the body temperature during cooling. Our conclusions from that
study were that a brain temperature of 20°C is safe for 60 minutes
of arrest, but it requires 60 minutes of cooling to reach. For 30
minutes of arrest, we found that we needed 30 minutes of cooling
for the brain temperature to reach 28°C. Our recommendation is
that it is always better to cool too long than too short a period of
time before arrest.
Dr Gaynor. We used NP temperature as our surrogate for brain
temperature. All patients but one were cooled at least 15 minutes
to an NP temperature of 18°C, and we used topical hypothermia to
the brain by packing the head in ice.
Dr Connolly. And how long did you cool, just 30 minutes?
Dr Gaynor. At least 15 minutes in all but one patient.
Dr Connolly. Before we had conditioned our dogs, many of the
dogs would seem all right and could run around, but this did not
demonstrate any damage supratentorially. Therefore, we needed to
train the dogs to do some fancy tricks, and then we could assume
that there had been absolutely no change in the brain. That is when
we concluded that 30 minutes was probably the minimum.
Dr Bradley S. Allen (Houston, Tex). As Dr Fraser and Dr
Hanley said yesterday, and Dr Jonas alluded to today, the devil
sometimes is in the details. I have two questions.
First, what pressure or flow did you use for your continuous
bypass patients? Moreover, did you monitor the pressure, as too
high or too low a pressure may be detrimental?
Second, since you saw marked variability in the continuous
profusion group, did you look at multiple variables, as Dr Jonas
recommended (ie, hematocrit, pressure, flow) to determine
whether any of those variables explained the variability in this
group?
Dr Gaynor. The pump strategies were not standardized. The
pump flow was at the discretion of the surgeon.
We did look at duration of cooling, lowest temperature, and
hematocrit. Although I think those are potentially important vari-
ables, I do not know of any data that correlate a certain flow or a
certain perfusion pressure during continuous bypass to indicate
that one pressure or one flow rate is better than another in a human
with long-term neurodevelopmental outcome. I do think that is
something that could be tested and standardized. It is a testable
hypothesis and those studies need to be done.
Dr Tara Karamlou (Toronto, Ontario, Canada). Did you look
at socioeconomic status? Did you look at a Hollingshead scale, or
how important is that?
Dr Gaynor. We did look at a Hollingshead scale. It did not
come out in the analysis, but I think there are some other studies
that suggest that at 1 year the environmental influences may not be
quite as great. We are now evaluating these children at 4 years, and
I will bet the Hollingshead scale will be a significant predictor at
4 years. However, we did include that in the analysis.
Dr Christo I. Tchervenkov (Montreal, Quebec, Canada). It
did not come up in the discussion, but what was the preoperative
status of the patient? We have shown that 60% of neonates and
40% of infants who have undergone a careful examination by a
neurologist and neuropsychologist are abnormal preoperatively.
Perhaps some of the variability in outcome could be explained by
the preoperative neurologic status of these patients. Have you done
any preoperative assessments?
Dr Gaynor. I agree entirely. There was not a formal preoper-
ative status, but I think the fact that lower birth weight Apgar
scores were associated with the worst outcome suggests that pre-
operative factors are an important determinant of outcome. Again,
back to our hypothesis, it is patient factors, things that exist before
and after the operation, as much as or more than what happens in
the operating room.
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